Eli Lilly and Company· @EliLillyandCo · X·· 2026-08-28精选AI 评分67
AI 导读
礼来宣布，FDA批准其旗下一款2型糖尿病药物的新适应症，用于降低心血管事件高风险的2型糖尿病成人患者发生主要心血管不良事件的风险。礼来指出，心脏病是2型糖尿病患者的主要死因。更多信息见 https://go.lilly.com/jdtqxp。
推荐理由
礼来官方披露FDA批准其2型糖尿病药物新增适应症，读者可了解该药在心血管风险人群中的定位。
正文
Heart disease is the leading cause of death for people living with type 2 diabetes. Today the FDA approved a new use for one of our type 2 diabetes medicines, lowering the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events. Read more: https://go.lilly.com/jdtqxp
来源：Eli Lilly and Company · x.com